To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
NCT00141375
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
- Must have received study medication under double-blind conditions.
- Patients cannot participate if they experienced a serious adverse event during the
previous double-blind BID study which was determined to be related to the study
medication.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Clermont-Ferrand,
- London, Ontario
- Beijing,
- Cheng Du Si Chaun,
- Guang Zhou,
- Nan Jing, Jiang Su,
- Qing Dao Shan Dong,
- Shang Hai,
- Shanghai,
- Tian Jin,
- Calgary, Alberta
- Calgary, Alberta
- Calgary, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Red Deer, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Kingston, Ontario
- London, Ontario
- Port Hope, Ontario
- Toronto, Ontario
- Charlottetown, Prince Edward Island
- Granby, Quebec
- Laval, Quebec
- Laval, Quebec
- Levis, Quebec
- Mirabel, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Sherbrook, Quebec
- Ste-Foy, Quebec
- Saskatoon, Saskatchewan
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury. | |||
Official Title ICMJE | An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury. | |||
Brief Summary | To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Neuropathic Pain | |||
Intervention ICMJE | Drug: Pregabalin | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 132 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | January 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Australia | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00141375 | |||
Other Study ID Numbers ICMJE | 1008-000-202 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |